Health care costs in people with diabetes and their association with glycemic control and kidney function

Diabetes Care

Volumn 36, Issue 5, 2013, Pages 1172-1180

  McBrien, Kerry A ^a   Manns, Braden J ^a,b   Chui, Betty ^c   Klarenbach, Scott W ^c   Rabi, Doreen ^a,b   Ravani, Pietro ^a,b   Hemmelgarn, Brenda ^a,b   Wiebe, Natasha ^c   Au, Flora ^a   Clement, Fiona ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ABORIGINE; ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; DRUG COST; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN TREATMENT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEINURIA; SOCIAL STATUS;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA;

EID: 84876802864     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0862     Document Type: Article

References (40)

1. Report from the National Diabetes Surveillance System. Diabetes in Canada, 2009 Public Health Agency of Canada, 2009
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
3. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: A population-based study. Lancet 2007;369:750-756 (Pubitemid 46321630)
4. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascu-lar comorbid conditions. Diabetes Care 2009;32:2187-2192
5. Simpson SH, Corabian P, Jacobs P, Johnson JA. The cost of major co-morbidity in people with diabetes melli-tus. CMAJ 2003;168:1661-1667 (Pubitemid 36801929)
6. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304 (Pubitemid 36993316)
7. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7
8. Pelletier EM, Shim B, Ben-Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics 2009; 27:479-490
9. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict mac-rovascular events in type 2 diabetes? Atherosclerosis 2011;218:13-18
10. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
11. Targher G, Zoppini G, Chonchol M, et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis 2011;21:294-301
12. Aagren M, Luo W. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. J Media Econ 2011;14:108-114
13. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20: 1847-1853 (Pubitemid 27522894)
14. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005;28:59-64 (Pubitemid 40095783)
15. Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: A retrospective analysis. Cost Eff Resour Alloc 2006;4:1
16. American Diabetes Association. Standards of medical care in diabetesd2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
17. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008;32 (Suppl. 1):S1-S201
18. Hemmelgarn BR, Clement F, Manns BJ, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol 2009;10: 30
19. Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care 1996;19:807-811 (Pubitemid 26286983)
20. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-516 (Pubitemid 41103345)
21. Johnson D, Jin Y, Truman C. Influence of aboriginal and socioeconomic status on birth outcome and maternal morbidity. J Obstet Gynaecol Can 2002;24:633-640
22. Pohar SL, Johnson JA. Health care utilization and costs in Saskatchewan's registered Indian population with diabetes. BMC Health Serv Res 2007;7:126
23. Government of Alberta-Health and Wellness. Premium assistance program: premium subsidy [Internet]. Available from http://www.health.alberta.ca/AHCIP/ premium-subsidy.html. Accessed 4 April 2011
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
25. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining co-morbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43: 1130-1139 (Pubitemid 41587600)
26. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
27. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl. 1):S1-S266
28. Duan N. Smearing estimate: A non-parametric retransformation method. J Am Stat Assoc 1983;78:605-610
29. National Health Expenditure Trends, 1975 to 2011. Ottawa, Ontario, 2011, CIHI2011
30. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004 (4):CD003418
31. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with met-formin monotherapy: A systematic review and mixed-treatment comparison meta-analysis. Open Med 2011;5:e35-e48
32. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-189 (Pubitemid 32048520)
33. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
34. de Galan BE, Perkovic V, Ninomiya T, et al.; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-892
35. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993;118:129-138
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462 (Pubitemid 23335891)
37. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartanin patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860
38. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
39. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and mi-crovascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-840 (Pubitemid 47362321)
40. Strippoli GF, Craig MC, Schena FP, Craig JC. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006; 17(Suppl. 2):S153-S155